To download PDF copies of dozens of vaccine package inserts such as the one I have excerpted for the shingles vaccine (Shingrix) that doctors and pediatricians are supposed to read before they administer any vaccine, go here:

http://www.vaccinesafety.edu/package_inserts.htm

and click the click entitled: Shingrix Varicella Zoster GlaxoSmithKline Sep 2018

EXCERPTS:

1. INDICATIONS AND USAGE
SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

Limitations of Use:
• SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

11. DESCRIPTION

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a sterile suspension for intramuscular injection. The vaccine is supplied as a vial of lyophilized recombinant varicella zoster virus surface glycoprotein E (gE) antigen component, which must be reconstituted at the time of use with the accompanying vial of AS01B adjuvant suspension component. The lyophilized gE antigen component is presented in the form of a sterile white powder. The AS01B adjuvant suspension component is an opalescent, colorless to pale brownish liquid supplied in vials.

The gE antigen is obtained by culturing genetically engineered Chinese Hamster Ovary cells, which carry a truncated gE gene, in media containing amino acids, with no albumin, antibiotics, or animal-derived proteins. The gE protein is purified by several chromatographic steps, formulated with excipients, filled into vials, and lyophilized.

CONTRAINDICATIONS -------------------
History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX. (4)

----------------- ADVERSE REACTIONS ----------------------
• Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%). (6.1)
• Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%). (6.1)